<DOC>
	<DOCNO>NCT00530530</DOCNO>
	<brief_summary>To demonstrate superiority ASP8825 placebo dose response patient restless legs syndrome</brief_summary>
	<brief_title>ASP8825 - Study Patients With Restless Legs Syndrome</brief_title>
	<detailed_description>Three dos ASP8825 compare placebo efficacy safety point view patient restless legs syndrome</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>Patients RLS , base International RSL Study Group Diagnostic Criteria History RLS symptoms least 15 night prior month , treatment , frequency symptom treatment start Documented RLS symptoms least 4 7 consecutive evenings/ night baseline study period A sleep disorder ( e.g. , sleep apnea ) may significantly affect assessment RLS A history RLS symptom augmentation endofdose rebound previous dopamine agonist treatment Neurologic disease movement disorder ( e.g. , diabetic neuropathy , Parkinson 's Disease , Multiple Sclerosis , dyskinesia dystonias</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ASP8825</keyword>
	<keyword>Restless legs Syndrome</keyword>
	<keyword>XP13512</keyword>
</DOC>